Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Destiny Delapa

Nurse Practitioner, Family Huntington, WV Nurse Practitioner

NPI 1710268925 CMS profile 11065853

422 Kinetic Park Dr, Ste B, Huntington, WV 25701

Open in the dashboard

General payments

$4,928

285 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Destiny Delapa of Huntington, WV is reported in the CMS Open Payments database as having received $4,928 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,307 77
2024 General $1,463 85
2023 General $1,453 88
2022 General $508 23
2021 General $196 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Destiny Delapa
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Destiny Delapa were reported at $1,307. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Destiny Delapa Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $196 $124 $35–$379 $132
2022 $508 $141 $44–$430 $149
2023 $1,453 $154 $49–$476 $160
2024 $1,463 $165 $51–$504 $164
2025 $1,307 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,297 81 payments
  2. AbbVie, Inc. $1,010 71 payments
  3. E.R. Squibb & Sons, L.L.C. $803 45 payments
  4. Amgen Inc. $280 13 payments
  5. Pfizer Inc. $192 10 payments
  6. Novartis Pharmaceuticals Corporation $183 8 payments
  7. LEO Pharma Inc. $177 9 payments
  8. Dermavant Sciences, Inc. $158 8 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $114 6 payments
  10. Sun Pharmaceutical Industries Inc. $114 5 payments
  11. Other $600 29 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,608 281 payments
  2. Education $320 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,220 73 payments
  2. SOTYKTU $803 45 payments
  3. RINVOQ $529 39 payments
  4. Otezla $280 13 payments
  5. SKYRIZI Immunology $215 10 payments
  6. CIBINQO $192 10 payments
  7. SKYRIZI Immunology $184 14 payments
  8. ADBRY $177 9 payments
  9. LITFULO $172 9 payments
  10. COSENTYX $161 7 payments
  11. Other $1,649 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

727

Median for Nurse Practitioner: 389

Drug cost

$184,841

Median for Nurse Practitioner: $21,885

Branded share of claims

4.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 32 $160,305
Fluorouracil Generic 67 $4,789
Calcipotriene Generic 19 $3,697
Tacrolimus Generic 19 $2,656
Azelaic Acid Generic 13 $1,842
Doxycycline Hyclate Generic 100 $1,768
Clindamycin Phosphate Generic 39 $1,693
Metronidazole Generic 31 $1,646
Triamcinolone Acetonide Generic 163 $1,366
Econazole Nitrate Generic 26 $1,316

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$82,188

Of which drugs: $6,632

Medicare patients

496

Average age 74

Services billed

5,143

279 women, 217 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 30%
Ischemic heart disease 22%
Chronic kidney disease 21%
Atrial fibrillation 18%
Cancer 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 14 3,400 $4,456

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $334
$334 — —
TREMFYA
  • Janssen Biotech, Inc. $322
$322 — —
RINVOQ
  • AbbVie, Inc. $176
$176 — —
Otezla
  • Amgen Inc. $123
$123 32 —
SKYRIZI
  • AbbVie, Inc. $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record